Clinical and cost efficacy of advanced wound care matrices for venous ulcers

Journal of Managed Care Pharmacy

Volumn 18, Issue 5, 2012, Pages 375-384

  Hankin, Cheryl S ^a   Knispel, John ^b   Lopes, Maria ^c   Bronstone, Amy ^a   Maus, Erik ^d  

^a BioMedEcon LLC   (United States)

^b Knispel Associates   (United States)

^c MMD Lopes LLC   (United States)

^d UNIVERSITY OF TEXAS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADVANCED WOUND CARE MATRIX; ARTICLE; BANDAGE; COMPRESSION THERAPY; COST EFFECTIVENESS ANALYSIS; FOLLOW UP; HEALTH CARE SYSTEM; HUMAN; LEG ULCER; SCORING SYSTEM; TREATMENT OUTCOME; WILSON SCORE; WOUND HEALING;

EID: 84864835746     PISSN: 10834087     EISSN: None     Source Type: Journal    
DOI: 10.18553/jmcp.2012.18.5.375     Document Type: Article

References (57)

1. Phillips TJ, Dover JS. Leg ulcers. J Am Acad Dermatol. 1991;25(6 Pt 1):965-87.
2. Jones KR. Why do chronic venous leg ulcers not heal? J Nurs Care Qual. 2009;24(2):116-24; quiz 125-26.
3. Kurz X, Kahn SR, Abenhaim L, et al. Chronic venous disorders of the leg: epidemiology, outcomes, diagnosis and management. Summary of an evidence-based report of the VEINES task force. Venous Insufficiency Epidemiologic and Economic Studies. Int Angiol. 1999;18(2):83-102.
4. Coon WW, Willis PW 3rd, Keller JB. Venous thromboembolism and other venous disease in the Tecumseh community health study. Circulation. 1973;48(4):839-46. Available at: http://circ.ahajournals.org/content/48/4/839.long. Accessed May 27, 2012.
5. Callam MJ, Harper DR, Dale JJ, Ruckley CV. Chronic ulcer of the leg: clinical history. Br Med J (Clin Res Ed). 1987;294(6584):1389-91. Available at: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1246555/pdf/bmjcred00022-0025.pdf. Accessed May 27, 2012.
6. Ongenae KC, Phillips TJ. Leg ulcer management. Emerg Med. 1993;25:45-53.
7. Olin JW, Beusterien KM, Childs MB, Seavey C, McHugh L, Griffiths RI. Medical costs of treating venous stasis ulcers: evidence from a retrospective cohort study. Vasc Med. 1999;4(1):1-7. Available at: http://vmj.sagepub.com/content/4/1/1.full.pdf. Accessed May 27, 2012.
8. Phillips T, Stanton B, Provan A, Lew R. A study of the impact of leg ulcers on quality of life: financial, social, and psychologic implications. J Am Acad Dermatol. 1994;31(1):49-53.
9. Vincent GK, Velkoff VA. The next four decades: the older population in the United States: 2010 to 2050. Current Population Reports. P25-1138. U.S. Census Bureau. 2010. Available at: http://www.census.gov/prod/2010pubs/p25-1138.pdf. Accessed May 27, 2012.
10. Wound Ostomy and Continence Nurses Society. Guideline for Management of Wounds in Patients with Lower-Extremity Venous Disease. Glenview, IL: Wound Ostomy and Continence Nurses Society (WOCN); 2005.
11. Robson MC, Cooper DM, Aslam R, et al. Guidelines for the treatment of venous ulcers. Wound Repair Regen. 2006;14(6):649-62.
12. Falanga V, Margolis D, Alvarez O, et al. Rapid healing of venous ulcers and lack of clinical rejection with an allogeneic cultured human skin equivalent. Human Skin Equivalent Investigators Group. Arch Dermatol. 1998;134(3):293-300.
13. Polignano R, Bonadeo P, Gasbarro S, Allegra C. A randomised controlled study of four-layer compression versus Unna's Boot for venous ulcers. J Wound Care. 2004;13(1):21-24.
14. Barwell JR, Davies CE, Deacon J, et al. Comparison of surgery and compression with compression alone in chronic venous ulceration (ESCHAR study): randomised controlled trial. Lancet. 2004;363(9424):1854-59.
15. Simka M. Cellular and molecular mechanisms of venous leg ulcers development-the "puzzle" theory. Int Angiol. 2010;29(1):1-19.
16. Loots MA, Lamme EN, Zeegelaar J, Mekkes JR, Bos JD, Middelkoop E. Differences in cellular infiltrate and extracellular matrix of chronic diabetic and venous ulcers versus acute wounds. J Invest Dermatol. 1998;111(5):850-57.
17. Herrick SE, Sloan P, McGurk M, Freak L, McCollum CN, Ferguson MW. Sequential changes in histologic pattern and extracellular matrix deposition during the healing of chronic venous ulcers. Am J Pathol. 1992;141(5):1085-95.
18. Bureau of Labor Statistics. Consumer price index. Available at: http://data.bls.gov/cgi-bin/surveymost?cu. Accessed May 27, 2012.
19. U.S. Food and Drug Administration. Guidance for industry: chronic cutaneous ulcer and burn wounds-developing products for treatment. June 2006. Available at: http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm071324.pdf. Accessed May 27, 2012.
20. Gelfand JM, Hoffstad O, Margolis DJ. Surrogate endpoints for the treatment of venous leg ulcers. J Invest Dermatol. 2002;119(6):1420-25. Available at: http://www.nature.com/jid/journal/v119/n6/pdf/5603355a.pdf. Accessed May 27, 2012.
21. Mostow EN, Haraway GD, Dalsing M, Hodde JP, King D. Effectivenessof an extracellular matrix graft (OASIS Wound Matrix) in the treatment of chronic leg ulcers: a randomized clinical trial. J Vasc Surg. 2005;41(5):837-43. Available at: http://download.journals.elsevierhealth.com/pdfs/journals/0741-5214/PIIS0741521405001813.pdf. Accessed May 27, 2012.
22. Kelechi TJ, Mueller M, Hankin CS, Bronstone A, Samies J, Bonhan PA. A randomized, investigator-blinded, controlled pilot study to evaluate the safety and efficacy of a poly-N-acetyl glucosamine-derived membrane material in patients with venous leg ulcers. J Am Acad Dermatol. 2012;66(6):e209-15.
23. Scherer SS, Pietramaggiori G, Matthews J, et al. Poly-N-acetyl glucosamine nanofibers: a new bioactive material to enhance diabetic wound healing by cell migration and angiogenesis. Ann Surg. 2009;250(2):322-30.
24. Scherer SS, Pietramaggiori G, Matthews JC, et al. Poly-N-acetyl glucosamine fibers induce angiogenesis in ADP inhibitor-treated diabetic mice. J Trauma. 2011;71(2 Suppl 1):S183-S86.
25. Lindner HB, Zhang A, Eldridge J, et al. Anti-bacterial effects of poly-Nacetyl- glucosamine nanofibers in cutaneous wound healing: requirement for Akt1. PLoS One. 2011;6(4):e18996. Available at: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3084735/pdf/pone.0018996.pdf. Accessed May 27, 2012.
26. Falanga V, Isaacs C, Paquette D, et al. Wounding of bioengineered skin: cellular and molecular aspects after injury. J Invest Dermatol. 2002;119(3):653-60. Available at: http://www.nature.com/jid/journal/v119/n3/pdf/5601606a.pdf. Accessed May 27, 2012.
27. Brown-Etris M, Cutshall W, Hiles MC. A new biomaterial derived from small intestine submucosa and developed into a wound matrix device. WOUNDS. 2002;14:150-66. Available at: http://www.medscape.com/viewarticle/437577. Accessed May 27, 2012.
28. Hart J, Silcock D, Gunnigle S, Cullen B, Light ND, Watt PW. The role of oxidised regenerated cellulose/collagen in wound repair: effects in vitro on fibroblast biology and in vivo in a model of compromised healing. Int JBiochem Cell Biol. 2002;34(12):1557-70.
29. Cullen B, Watt PW, Lundqvist C, et al. The role of oxidised regenerated cellulose/collagen in chronic wound repair and its potential mechanism of action. Int J Biochem Cell Biol. 2002;34(12):1544-56.
30. Cullen B, Smith R, McCulloch E, Silcock D, Morrison L. Mechanism of action of PROMOGRAN, a protease modulating matrix, for the treatment of diabetic foot ulcers. Wound Repair Regen. 2002;10(1):16-25.
31. Margolis DJ, Allen-Taylor L, Hoffstad O, Berlin JA. The accuracy of venous leg ulcer prognostic models in a wound care system. Wound Repair Regen. 2004;12(2):163-68.
32. Warriner RA. A new algorithm for the evaluation and treatment of venous leg ulcer patients in the outpatient wound care clinic. WOUNDS. 2010;56(Suppl):8-11. Available at: http://www.o-wm.com/files/Covidien_CVR1_lr.pdf. Accessed May 27, 2012.
33. Aetna. Clinical policy bulletin: wound care. Number: 0244. Last reviewed May 13, 2011. Available at: http://www.aetna.com/cpb/medical/data/200_299/0244.html. Accessed May 27, 2012.
34. Independence Blue Cross. Wound care: bioengineered skin substitutes. Medical policy bulletin. Policy no. 11.08.20i. Effective January 1, 2012. Available at: http://medpolicy.ibx.com/policies/mpi.nsf/0/85256AA800623D7A85257968004F7400?OpenDocument. Accessed May 27, 2012.
35. WPS Health Insurance Medicare. Application of bioengineered skin substitutes (L30135). Updated May 3, 2012. Available at: http://www.wpsmedicare.com/part_b/policy/active/local/l30135_gsurg052.shtml. Accessed May 27, 2012.
36. TrailBlazer Health Enterprises. LCD 3332: bioengineered skin substitutes. Revised January 1, 2012. Available at: http://www.trailblazerhealth.com/Tools/LCDs.aspx?ID=3332. Accessed May 27, 2012.
37. UnitedHeathcare. Coverage summary. UnitedHealthcare Medicare Advantage Plans: wound treatments. Revised April 26, 2011. Available at: https://www.unitedhealthcareonline.com/ccmcontent/ProviderII/UHC/en-US/Assets/ProviderStaticFiles/ProviderStaticFilesPdf/Tools%20and%20Resources/Policies%20and%20Protocols/UnitedHealthcare%20Medicare%20Coverage/Wound_Care_UHCMA_CS.pdf. Accessed May 27, 2012.
38. Red Book Online. Ann Arbor, MI: Thomson Reuters; 2011. Available at: http://www.redbook.com/redbook/index.html. Accessed May 27, 2012.
39. Shire Pharmaceuticals. Top-line results from pivotal trial of Dermagraft for venous leg ulcers. August 24, 2011. Available at: http://www.shire.com/shireplc/en/investors/investorsnews/irshirenews?id=519. Accessed May 27, 2012.
40. Apligraf [package insert]. Organogenesis Inc. December 2010. Available at: http://www.apligraf.com/professional/pdf/prescribing_information.pdf. Accessed May 27, 2012.
41. U.S. Food and Drug Administration. Special 510(k) summary. Oasis Wound Matrix. July 19, 2006. Available at: http://www.accessdata.fda.gov/cdrh_docs/pdf6/K061711.pdf. Accessed May 27, 2012.
42. U.S. Food and Drug Administration. 510(k) summary. Talymed. July 28, 2010. Available at: http://www.accessdata.fda.gov/cdrh_docs/pdf10/K102002.pdf. Accessed May 27, 2012.
43. U.S. Food and Drug Administration. Apligraf (Graftskin). Summary of effectiveness and safety data. PMA No. P950032. Organogenesis Inc. May 22, 1998. Available at: http://www.accessdata.fda.gov/cdrh_docs/pdf/P950032b.pdf. Accessed May 27, 2011.
44. McQuay HJ, Moore RA. Using numerical results from systematic reviews in clinical practice. Ann Intern Med. 1997;126(9):712-20.
45. Cook R, Sackett D. The number needed to treat: a clinically useful measure of treatment effect. BMJ. 1995;310(6977):452-54. Available at: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2548824/pdf/bmj05580-0046.pdf. Accessed May 27, 2012.
46. Bender R. Calculating confidence intervals for the number needed to treat. Control Clin Trials. 2001;22(2):102-10.
47. Newcombe RG. Interval estimation for the difference between independent proportions: comparison of eleven methods. Stat Med. 1998;17(8):873-90.
48. Tennvall GR, Hjelmgren G, Öien R. The cost of treating hard-to-heal venous leg ulcers: results from a Swedish survey. World Wide Wounds. November 2006. Available at: http://www.worldwidewounds.com/2006/november/Tennvall/Cost-of-treating-hard-to-heal-venous-leg-ulcers.html. Accessed May 27, 2012.
49. McAlister FA. The "number needed to treat" turns 20-and continues to be used and misused. CMAJ. 2008;179(6):549-53.
50. Margolis DJ, Berlin JA, Strom BL. Which venous leg ulcers will heal with limb compression bandages? Am J Med. 2000;109(1):15-19.
51. Phillips TJ, Machado F, Trout R, Porter J, Olin J, Falanga V. Prognostic indicators in venous ulcers. J Am Acad Dermatol. 2000;43(4):627-30.
52. Meaume S, Couilliet D, Vin F. Prognostic factors for venous ulcer healing in a non-selected population of ambulatory patients. J Wound Care. 2005;14(1):31-34.
53. Milic DJ, Zivic SS, Bogdanovic DC, Karanovic ND, Golubovic ZV. Risk factors related to the failure of venous leg ulcers to heal with compression treatment. J Vasc Surg. 2009;49(5):1242-47.
54. White R. Hard-to-heal wounds: results of an international survey. Wounds UK. 2011;7(4):22-31.
55. Snyder DL, Sullivan N, Schoelles KM. Skin substitutes for treating chronic wounds (draft). Technology assessment report. Project ID: HCPR0610. Agency for Healthcare Research and Quality. December 22, 2011. Available at: http://www.elsevierbi.com/~/media/Supporting%20Documents/The%20Gray%20Sheet/38/2/skinsubstitutes_ahrq.pdf. Accessed May 27, 2012.
56. Mathias SD, Prebil LA, Boyko WL, Fastenau J. Health-related quality of life in venous leg ulcer patients successfully treated with Apligraf: a pilot study. Adv Skin Wound Care. 2000;13(2):76-78.
57. Collins L, Seraj S. Diagnosis and treatment of venous ulcers. Am Fam Physician. 2010;81(8):989-96. Available at: http://www.aafp.org/afp/2010/0415/p989.pdf. Accessed May 27, 2012.